Psychiatry AtlasMedication guide · United States

Anesthetic sometimes used off-label for depression

Ketamine (Ketalar)

Generic name
racemic ketamine (as ketamine hydrochloride)
Brand names
Ketalar
Medication class
Anesthetic sometimes used off-label for depression
Forms covered
Ketalar injection

Article updated: 2026-10-30 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

High Alert

  • Acute care, intravenous anesthetic use: dosing or administration errors can impair breathing and circulation. Trained staff and appropriate monitoring are required.

Ketamine is an anesthetic sometimes used off-label for treatment-resistant depression. Explore evidence, supervised treatment, safety, and how it differs from esketamine.

What to expect: Some people in supervised depression trials improve within hours or days; others do not.

Warning signs
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Anesthesia — Patients selected for appropriate diagnostic or surgical anesthesia; safety and effectiveness below age 16 are not established. Anesthetic use, induction or supplementation. This is not psychiatric approval.Ketalar injection.

Other uses (off-label)

Off-label means a medicine is prescribed for a use, age group or form that is not included in its FDA approval.

  • Specialist treatment of depression — Selected adults after specialist assessment. Supervised IV ketamine has evidence for short-term benefit in some people with treatment-resistant depression; durability and long-term regimens remain uncertain. There is no FDA psychiatric approval.Ketalar injection.

Read more: Major Depression.

What should I expect?

Some people in supervised depression trials improve within hours or days; others do not. Improvement can fade, and the safest long-term schedule remains uncertain.

An altered or detached feeling during a session is not proof of an antidepressant response. Review mood, functioning, adverse effects and how long any benefit lasts with the treatment service.

How do I take it safely?

Psychiatric ketamine treatment is off-label and needs an appropriately equipped supervised service. There is no FDA-approved ketamine depression dose or maintenance schedule. Anesthetic dosing and evidence for one route must not be transferred to another.

The service should review diagnosis, suicide risk, blood pressure, heart and breathing health, psychosis or mania, substance use, pregnancy and all medicines. Alcohol, opioids, benzodiazepines and other sedatives can deepen sedation or suppress breathing; stimulants may increase cardiovascular effects.

During treatment and recovery, trained staff monitor consciousness, breathing, oxygenation, pulse and blood pressure. Arrange a safe journey home and follow the service’s driving and food instructions. Contact the service about missed sessions; never make up a dose yourself.

Repeated treatment requires reassessment of benefit, urinary symptoms, cognition and misuse, with baseline and periodic liver tests as directed in current labeling. Discuss pregnancy or breastfeeding because safety information is limited. Compounded oral, sublingual or nasal products are not FDA-approved and do not have Spravato’s product-specific evidence.

Do not use when a significant rise in blood pressure would be a serious hazard. Theophylline and aminophylline must not be coadministered under the current Ketalar label because of seizure risk.

Do not use this product after a known allergy to its active medicine or ingredients; tell the pharmacist about previous medication reactions.

What side effects should I know about?

  • Dissociation, dizziness, nausea, vomiting, perceptual disturbance and transient increases in blood pressure or pulse.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Breathing difficulty, inability to wake, collapse, severe chest pain, seizure, sudden severe headache or new weakness requires immediate medical assessment. Treatment can impair awareness and sharply raise blood pressure.
  • Report painful or bloody urination, persistent urinary symptoms, abdominal pain or jaundice promptly. Repeated exposure can injure the urinary tract, liver or bile ducts. Misuse, tolerance and dependence are also risks.
  • Ketamine has not been established to prevent suicide. Urgent psychiatric care and hospitalization must not be delayed when needed, even after temporary mood improvement.
  • Ketalar’s label cautions about possible effects on the developing brain after repeated or prolonged anesthetic exposure in very young children. The warning draws substantially on animal research, and its meaning for children remains uncertain. Necessary anesthesia should not be delayed because of this concern; clinicians discuss the benefits and timing for the particular child.

What else should I know to stay safe?

  • Do not use when a significant blood-pressure rise would pose a serious hazard or after ketamine or ingredient allergy. Cardiovascular or brain-vessel disease, psychosis or mania, substance-use history, liver disease and pregnancy or breastfeeding require careful assessment.
  • Psychiatric treatment requires an appropriately equipped supervised service, with monitoring of awareness, breathing, oxygen levels, pulse and blood pressure. Alcohol, opioids, benzodiazepines and other sedatives increase risk; theophylline and aminophylline must not be coadministered under the current Ketalar label.
  • Repeated treatment needs baseline and periodic liver tests and review of cognition, urinary symptoms, misuse and sustained benefit. Arrange safe transport and follow driving restrictions. There is no FDA-approved depression dosing schedule; compounded products and anesthetic doses must not be treated as equivalent psychiatric regimens.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • The intensity of dissociation is not a treatment target or a reason to seek a higher dose.
  • An infusion study does not establish that a compounded lozenge or nasal spray has the same effectiveness, safety or dose.
  • A short-lived improvement still needs a continuing care plan, including urgent psychiatric care when necessary.

How does it work?

Ketamine changes how nerve cells communicate using glutamate, a chemical messenger. It reduces activity through NMDA receptors, one type of protein that responds to glutamate. This action is established, but the changes that lead to an antidepressant effect in people are not fully understood.

Explore medication science

How was this medicine developed?

Ketamine entered US medicine as an anesthetic in 1970. Research later explored rapid antidepressant effects, but its anesthesia approval did not expand to depression. Esketamine nasal spray has a separate regulatory history and indication.

How do I say the name?

Ketamine: KEE-tuh-meen. Capital letters show the stressed syllable.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Ketalar: current US prescribing information (revised March 2026)
  2. Ketamine hydrochloride — NCI Dictionary of Cancer Terms
  3. Ketalar FDA prescribing information
  4. Drugs@FDA: FDA-Approved Drugs
  5. Ketalar: Package Insert / Prescribing Information / MOA
  6. Spravato: current US prescribing information (revised March 2026)
  7. FDA June 2026 warning letter: ketamine approval status and unapproved products
  8. Ketamine and neural changes: animal research and its limits
  9. Ketamine: updated government review of use, harms and controlled-drug status
  10. Ketamine versus ECT for nonpsychotic treatment-resistant major depression (randomised trial, 2023)
  11. Depression: treatment and brain stimulation options
  12. Compounding risk alerts, including ketamine oral formulations and nasal sprays
  13. Oral prolonged-release ketamine for treatment-resistant depression (randomised trials, 2026)
  14. CBT after ketamine: small proof-of-concept randomised clinical trial
  15. What Is a Neurotransmitter? — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How Neurotransmitters Work; Types of Neurotransmitters..

  16. Ketamine Lifts Depression via a Byproduct of its Metabolism — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Mouse experiments involving hydroxynorketamine and AMPA receptors; confirmation in humans explicitly pending..

  17. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Abstract: channel-opening experiments and conclusions..

  18. Structural basis for channel gating and blockade in tri-heteromeric GluN1-2B-2D NMDA receptor — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Summary; Introduction; S-(+)-ketamine closes the GluN1a-2B-2D NMDAR channel gate and blocks the pore..

  19. ISMP List of Confused Drug Names
  20. ISMP List of High-Alert Medications in Acute Care Settings
  21. NIMH: Understanding psychosis

Giving medicine safely to children: family guide (PDF, 3 pages)

Ketamine vs Esketamine

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top